New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.
Milk of calcium developed in 2 children with juvenile dermatomyositis. The fluid of the collection contained macrophages, interleukin-6, IL-1, and tumor necrosis factor. The patient who had dystrophic calcinosis had a dramatic improvement with the introduction of alendronate. These findings suggest that calcinosis of juvenile dermatomyositis may be mediated by activated macrophages and that alendronate can be an effective treatment for this condition.
Mukamel
M
M
Pediatric Rheumatology Unit, the Pediatric Imaging Department, and Day Care Unit, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.
Horev
G
G
Mimouni
M
M
D000293:Adolescent; D019386:Alendronate / Q000627:therapeutic use*; D002114:Calcinosis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D003882:Dermatomyositis / Q000150:complications*; D006801:Humans; D007375:Interleukin-1 / Q000032:analysis; D008264:Macrophages; D008297:Male; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D019386:Alendronate